scholarly journals Clinical features of severe respiratory failure in children at 37 weeks’ gestational age

2020 ◽  
Vol 9 (3) ◽  
pp. 26-32
Author(s):  
A. A. Greshilov ◽  
P. I. Mironov ◽  
V. R. Amirova ◽  
J. Z. Il’ina
Keyword(s):  
Respiratory Failure ◽  
Clinical Features ◽  
Gestational Age ◽  
Severe Respiratory Failure

Intracranial Hemorrhage During Extracorporeal Membrane Oxygenation in Neonates

PEDIATRICS ◽  
1986 ◽  
Vol 78 (4) ◽  
pp. 699-704
Author(s):  
Robert E. Cilley ◽  
Joseph B. Zwischenberger ◽  
Alice F. Andrews ◽  
Richard A. Bowerman ◽  
Dietrich W. Roloff ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Extracorporeal Membrane Oxygenation ◽  
Intracranial Hemorrhage ◽  
Gestational Age ◽  
Retrospective Review ◽  
The Other ◽  
Severe Respiratory Failure ◽  
Membrane Oxygenation

Intracranial hemorrhage is a complication of extracorporeal membrane oxygenation for the treatment of neonatal respiratory failure. A retrospective review of 35 neonates treated with extracorporeal membrane oxygenation was performed; ten had intracranial hemorrhage. Infants with intracranial hemorrhage had lower birth weights and were gestationally younger than infants with intracranial hemorrhage. Eight of eight neonates of less than 35 weeks' gestational age sustained intracranial hemorrhage. Six died immediately after extracorporeal membrane oxygenation was stopped. Two lived less than 1 year. Two of 27 neonates older than 34 weeks' gestational age sustained intracranial hemorrhage. One child is normal, the other died at 18 months of age. Based on the results of this study, the risk of intracranial hemorrhage appears low in neonates of greater than 34 weeks' gestational age who undergo extracorporeal membrane oxygenation treatment for severe respiratory failure. The use of extracorporeal membrane oxygenation, as it is presently performed, is contraindicated in neonates of less than 35 weeks' gestational age because of the risk of intracranial hemorrhage.

scholarly journals RISK FACTORS FOR DEVELOPMENT OF SEVERE RESPIRATORY FAILURE IN NEWBORNS OF 37-WEEK GESTATIONAL AGE

2019 ◽  
Vol 16 (4) ◽  
pp. 19-23
Author(s):  
P. I. MIRONOV ◽  
◽  
E. Z. IL'INA ◽  
T. V. SAUBANOVA ◽  
A. A. GRESHILOV ◽  
...  
Keyword(s):  
Risk Factors ◽  
Respiratory Failure ◽  
Gestational Age ◽  
Severe Respiratory Failure

scholarly journals CLINICAL FEATURES OF SEVERE COVID-19 WITH LETHAL OUTCOME IN VOLYN REGION RESIDENTS

2021 ◽  
Vol 29 (2) ◽  
pp. 16-24
Author(s):  
O. K. Yakovenko ◽  
O. G. Khanin ◽  
V. V. Lotysh ◽  
S. L. Gryf
Keyword(s):  
Renal Failure ◽  
Respiratory Failure ◽  
Clinical Features ◽  
Demographic Data ◽  
Demographic Factors ◽  
Lung Pathology ◽  
Severe Respiratory Failure ◽  
Lethal Outcome ◽  
Laboratory Markers ◽  
D Dimer

On March, 11 2020 WHO declared novel SARS-CoV-2 outbreak as pandemic (Coronavirus disease, COVID-19), which took away almost 4 million lives of our planet population. Management of severe COVID-19 represents the most challenging problem being associated with high level of mortality. Aim of the study: to assess the clinical features of severe COVID-19, demographic factors, laboratory markers and lung pathology findings associated with severe course and lethal outcome. Material and methods. In retrospective cohort survey we recruited 171 adult patients (age > 18 years) with severe COVID-19, admitted to 2nd infection disease department of municipal hospital �Volyn regional clinical hospital� (CE �Voklen�). 101 patients were discharged after completion of treatment. 70 patients died. In two groups (discharged or deceased) we analyzed demographic data, clinical diagnosis, comorbidity and complications, duration of disease and hospital stay, body temperature at admission, blood oxygen saturation at admission and during the course of treatment, major laboratory parameters (WBC, neutrophils, lymphocytes, thrombocytes, RBC, neutrophil/lymphocyte ration (NLR), C-RP, AST, ALT, creatinine, total protein, blood glucose and procalcitonin). Almost all patients were tested for D-dimer, lupus anticoagulant (LA) and blood gases. In part of deceased patients (n=10) an autopsy was performed with subsequent lung tissue histological examination. Results and discussion. Acute respiratory distress syndrome (ARDS) and severe respiratory failure were the major cause of death from COVID19. Concomitant conditions, which worsened the clinical course and prognosis: renal failure, thrombotic events, in part associated with elevation of D-dimer and LA, neoplasm, cardiovascular conditions and diabetes mellitus. Female sex and younger age were the demographic factors of favorable outcome. Leukocytosis, high NLR, increased creatinine (as an indicator of renal failure), hypoproteinemia and high serum glucose level were the laboratory markers of unfavorable prognosis. LA, associated with severe respiratory failure, stroke and vascular thrombosis, were found positive in 40 % of patients with severe COVID-19. Key words: COVID-19, severe course, mortality, prognosis factors.

Favorable Anakinra Responses in COVID-19 Patients with Severe Respiratory Failure

2020 ◽  
Author(s):  
George Dimopoulos ◽  
Quirijn de Mast ◽  
Nikolaos Markou ◽  
Maria Theodorakopoulou ◽  
Apostolos Komnos ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Severe Respiratory Failure

scholarly journals 630. A 5-mRNA host response whole-blood classifier trained using patients with non-COVID-19 viral infections accurately predicts severity of COVID-19

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S375-S376
Author(s):  
ljubomir Buturovic ◽  
Purvesh Khatri ◽  
Benjamin Tang ◽  
Kevin Lai ◽  
Win Sen Kuan ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Respiratory Failure ◽  
Viral Infections ◽  
Lamp Assay ◽  
Training Data ◽  
Diagnostic Tools ◽  
Severe Respiratory Failure ◽  
Proof Of Concept ◽  
Risk Of Death ◽  
Qpcr Platform

Abstract Background While major progress has been made to establish diagnostic tools for the diagnosis of SARS-CoV-2 infection, determining the severity of COVID-19 remains an unmet medical need. With limited hospital resources, gauging severity would allow for some patients to safely recover in home quarantine while ensuring sicker patients get needed care. We discovered a 5 host mRNA-based classifier for the severity of influenza and other acute viral infections and validated the classifier in COVID-19 patients from Greece. Methods We used training data (N=705) from 21 retrospective clinical studies of influenza and other viral illnesses. Five host mRNAs from a preselected panel were applied to train a logistic regression classifier for predicting 30-day mortality in influenza and other viral illnesses. We then applied this classifier, with fixed weights, to an independent cohort of subjects with confirmed COVID-19 from Athens, Greece (N=71) using NanoString nCounter. Finally, we developed a proof-of-concept rapid, isothermal qRT-LAMP assay for the 5-mRNA host signature using the QuantStudio 6 qPCR platform. Results In 71 patients with COVID-19, the 5 mRNA classifier had an AUROC of 0.88 (95% CI 0.80-0.97) for identifying patients with severe respiratory failure and/or 30-day mortality (Figure 1). Applying a preset cutoff based on training data, the 5-mRNA classifier had 100% sensitivity and 46% specificity for identifying mortality, and 88% sensitivity and 68% specificity for identifying severe respiratory failure. Finally, our proof-of-concept qRT-LAMP assay showed high correlation with the reference NanoString 5-mRNA classifier (r=0.95). Figure 1. Validation of the 5-mRNA classifier in the COVID-19 cohort. (A) Expression of the 5 genes used in the logistic regression model in patients with (red) and without (blue) mortality. (B) The 5-mRNA classifier accurately distinguishes non-severe and severe patients with COVID-19 as well as those at risk of death. Conclusion Our 5-mRNA classifier demonstrated very high accuracy for the prediction of COVID-19 severity and could assist in the rapid, point-of-impact assessment of patients with confirmed COVID-19 to determine level of care thereby improving patient management and healthcare burden. Disclosures ljubomir Buturovic, PhD, Inflammatix Inc. (Employee, Shareholder) Purvesh Khatri, PhD, Inflammatix Inc. (Shareholder) Oliver Liesenfeld, MD, Inflammatix Inc. (Employee, Shareholder) James Wacker, n/a, Inflammatix Inc. (Employee, Shareholder) Uros Midic, PhD, Inflammatix Inc. (Employee, Shareholder) Roland Luethy, PhD, Inflammatix Inc. (Employee, Shareholder) David C. Rawling, PhD, Inflammatix Inc. (Employee, Shareholder) Timothy Sweeney, MD, Inflammatix, Inc. (Employee)

scholarly journals Proven COVID‐19‐associated pulmonary aspergillosis in patients with severe respiratory failure

Mycoses ◽  
2021 ◽  
Author(s):  
Francesco Fortarezza ◽  
Annalisa Boscolo ◽  
Federica Pezzuto ◽  
Francesca Lunardi ◽  
Manuel Jesús Acosta ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Severe Respiratory Failure ◽  
Pulmonary Aspergillosis

scholarly journals Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case–control study

2021 ◽  
pp. jclinpath-2020-207356
Author(s):  
Matthew N Klein ◽  
Elizabeth Wenqian Wang ◽  
Paul Zimand ◽  
Heather Beauchamp ◽  
Caitlin Donis ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Clinical Outcomes ◽  
Ecmo Support ◽  
Survival Duration ◽  
Severe Respiratory Failure ◽  
Loess Regression ◽  
Antibody Titres ◽  
Similar Survival ◽  
Kinetics Of ◽  
Control Study

AimsWhile the SARS-CoV-2 pandemic may be contained through vaccination, transfusion of convalescent plasma (CCP) from individuals who recovered from COVID-19 (CCP) is considered an alternative treatment. We investigate if CCP transfusion in patients with severe respiratory failure increases plasma titres of SARS-CoV-2 antibodies and improves clinical outcomes.MethodsPatients with COVID-19 (n=34) were consented for CCP transfusion and serial blood draws pretransfusion and post-transfusion. Plasma SARS-CoV-2 antireceptor binding domain (RBD) IgG and IgM titres were measured by ELISA serially, and compared with serial plasma titre levels from control patients (n=68). The primary outcome was survival at 30 days, and secondary outcomes were length of ventilator and/or extracorporeal membrane oxygenation (ECMO) support, length of stay (LOS) in the hospital and in the intensive care unit (ICU). Outcomes were compared with matched control patients (n=34). Kinetics of antibodies and clinical outcomes were compared using LOess regression and ORs, respectively.ResultsPrior to CCP transfusion, 74% of patients were anti-RBD seropositive for IgG (median 1:3200), and 81% were anti-RBD IgM seropositive (median 1:320), while 16% were seronegative. The kinetics of antibody titres in CCP recipients were similar to controls. CCP recipients presented with similar survival, duration on ventilatory and/or ECMO support, as well as ICU and hospital LOS compared with controls.ConclusionsCCP transfusion did not increase the kinetics of SARS-CoV2 antibodies and did not result in improved clinical outcomes in patients with COVID-19 with severe respiratory failure, suggesting that CCP may not be indicated in this category of patients.

Sign in / Sign up

Export Citation Format

Share Document